Tagged: pharma

A Big Welcome To GSK’s New CEO… Emma Walmsley…



GSK welcomed a new CEO today– Emma Walmsley. Emma owns in excess of 200,000 GSK shares, and at £16 quid a share, she’ll be rolling in dough in no time, so you can be sure she’ll be looking after GSK’s interests just as as good as Andrew and JP did… the GSK cash cow’s gotta keep on rolling… never mind the harm drugs such as Seroxat cause vulnerable people… just make damn sure that cash keeps rolling in…

Do you think GSK’s corporate culture is going to change now that a woman is going to be in charge when Mr Witty leaves GSK in 2017?

Simple answer: “money is the root of all evil”…

See Whistleblower Greg Thorpe’s Department of Justice complaint (link below) for a colossus lesson in the meaning of that phrase…

https://truthman30.wordpress.com/2015/08/28/whistleblower-greg-thorpes-7th-ammended-complaint/

cs08sgruaamzipg

Image kindly borrowed from https://twitter.com/NeLLLieBly

The Life Of Piacentile: American Doctor (Dr Joe Piacentile’s) Lucrative ‘Whistle Blowing Career’…


Joe-Piacentile-02

“…Piacentile is what you might call a professional whistleblower. According to his lawyer, David Stone of the Short Hills, New Jersey, office of Boies, Schiller & Flexner, Piacentile used to be one of the doctors courted with lavish attention by drug companies. Then he stopped going to the fancy parties and started filing False Claims Act suits based on what he’d seen and learned. Not all of his cases have been as spectacularly successful as those against Medco, Bristol-Myers, and Cephalon, but with one-third of the government’s recovery going to whistle-blowers in successful cases, Piacentile doesn’t need to win ’em all…”

“Piacentile is a “serial filer” of whistle-blower complaints, having lodged at least 13 such cases against various companies in federal courts, prosecutors said in documents filed in November seeking to dismiss the case”…


http://www.gpo.gov/fdsys/pkg/FR-1997-07-01/html/97-17152.htm

DEPARTMENT OF JUSTICE

Drug Enforcement Administration
[Docket No. 96-37]


Joseph M. Piacentile, M.D.; Revocation of Registration
-----------------------------------------------------------------------

GSKGSK1

American culture seems to be all about money worship, and although we live in an extremely materialistic world generally and greed is rampant globally,  no place on the planet does greed quite like the Americans.

When I read articles about GSK’s 3 Billion dollar fine, or about people like Joe Piacentile, the articles  invariably mention money in amounts of millions, and (in the case of GSK) often billions too. These amounts of money are unfathomably alien to me. I don’t come in contact with figures containing multiple zeros. Two or three figure sums are a big deal to me; a four figure sum is a lot to me. I just can’t imagine dealing with seven or eight figure sums. I don’t even think I’d be comfortable being rich anyhow. There is too much inequality in this world, and I can’t bear inequality, it’s inequality, and the hoarding of wealth by the few which has the planet in the state its in. The hoarding of wealth and accumulation of stuff, just adds to the landfills. It’s all just more waste, more damage to the environment.

Furthermore, I certainly wouldn’t want to be driven or blinded by money  and thankfully it’s just never been a main motivator for me. I’ve seen people ruined by money, and destroyed by greed; some of them were members of my own family. There is much humility in knowing that greed will never consume you.

Greed consumes the soul.

Money seems to taint almost everyone who comes under its spell. It seems to be human nature for some, to always want more and more.

For some people, enough is never enough.

Dr Joe Piacentile, is (what some journalists have called) a ‘professional whistle blower’.  It is estimated that Piacentile has collected up to 17 million, or more, from his various whistle blowing adventures against pharmaceutical companies over the years.

I can understand one individual blowing the whistle against one pharmaceutical company because perhaps they saw some underhanded, illegal or unethical behaviour, and they decided to report it, but how can one person be involved in several different claims against several different companies at different times in their life?

Is this just cynical opportunism?

Interestingly, on Piacentile’s own web-site (‘Whistle-blowers Against Fraud’), he seems to semi-admit, that it was his company’s own foray into medicaid fraud (‘falsifying medicaid forms’) which first opened the good doctor’s eyes into the mechanics of how the justice system investigates these types of crimes. This, it seems, led Percentile, to the epiphany that there was considerably more money to be made in blowing the lid on fraud then there was in committing it, and 23 years later, Piancentile is now a multi-millionaire from his long and lucrative whistle blowing career.

The American dream, is paved with stories like this isn’t it? In America the harder your neck,  and the more dog eat dog you are, the more you are rewarded- it seems..

From the blurb on his own site (Piacentile foundation), Joe tells us:

“...Joseph Piacentile, M.D., who goes simply by “Dr. Joe,” is the Founder and CEO of Whistleblowers Against Fraud (“WAF”). Dr. Joe has dedicated more than 23 years of his professional career to seeking justice against those who commit fraud against the U.S. government. Dr. Joe has assisted the U.S. government in recovering more than $9 billion. Fighting fraud alongside those whistleblowers courageous enough to step forward and pursue justice is Dr. Joe’s passion.

“…In the mid-1980s, Dr. Joe was a partner in a national durable medical equipment company. In charge of a sales force of 160 employees, Dr. Joe grew sales from $1 million to $20 million in a mere three years. However, this early success did not end well. Dr. Joe and his partners each pled guilty to one count of fraud for reportedly “falsifying Medicare forms.” This brush with the justice system opened Dr. Joe’s eyes to the real damages caused by fraud and gave him a front row seat in observing the inner workings of the justice system’s prosecution of such crimes.”…


A recent article from NBC News reports that Dr Joe (as he likes to be called) attempted to donate $100,000 dollars to President Obama, in the hope that he could swing a ‘presidential pardon’ for his conviction in 1991 for medicaid fraud and tax evasion-

Obama’s fundraisers returned the check and NBC Reported that:

“…In December, Picacentile filed an application with the Justice Department seeking a pardon from Obama in which he expressed remorse over his 1991 felony convictions…”

“The bottom line is that I was the president of a corrupt company that ripped off Medicare for millions of dollars,” he wrote in the application, a copy of which was obtained for NBC News…”

 “… On Feb. 6, with the pardon application pending, Piacentile wrote a $100,000 check to Organizing for Action. The emails obtained by NBC News show that Piacentile’s check was written in response to an OFA fundraising appeal for the dinner and reception with Obama…”

“It is $25,000 per person to attend and for those that raise or write $100K, there will be small clutch with the president,” Maltzman wrote in a Jan. 15 email to another New Jersey doctor and potential donor, Munr Kazmir, who was an acquaintance of Piacentile and invited him to be his guest at the dinner…”


Not content with his 23 years of ‘professional whistle blowing, Dr Joe now offers advice to other potential whistleblowers, through his consultancy role. How much income Dr Joe receives from his ‘whistleblowers against fraud’ enterprise is anyone’s guess, however it seems that Dr Joe also has a somewhat charitable side to him (according to his website anyhow), and apparently he also has a keen interest in ‘social justice’ too.

“…But there is a darker perspective on Joseph Piacentile. Unlike most qui tam relators, he doesn’t blow the whistle as an employee or business partner of the companies he has sued. Instead he relies on secondhand information collected through his own investigations. (Piacentile declined to comment for this article.) Defense counsel call him a professional mudslinger; some qui tam lawyers and former government lawyers say that he’s a parasitic bully who files vague or questionable complaints and then pushes his way into settlements based on his qui tam savvy and his willingness to litigate. And Piacentile has a criminal history of his owna 1991 conviction on fraud and tax charges–which some lawyers say can undercut his credibility as a plaintiff”..

It seems to me that Piacentile is perhaps more interested in his cut from the many cases he has been involved in, then genuinely trying to expose the misdeeds of pharmaceutical companies. I have not seen any articles, websites, or videos of Piacentile, talking about how the fraudulent behaviour of pharmaceutical companies harms patients. I have not seen him asking for the jailing of CEO’s. I have not seen him campaign for patients’ rights, or the rights of those harmed by dangerous drugs like Paxil/Seroxat. Surely, some of this 17 million he received from his various whistle blower suits, could have been spent on exposing the dangers patients face when dealing with these sociopathic drug companies? He is, after all, supposedly a Doctor? If Piacentile was genuinely interested in exposing the dirty tricks of drug companies, and protecting patients from harm, then perhaps he would have invested more time, and money, into activism?

Just a thought..

I understand that some might argue, that people like Dr Joe, are doing a public service, and it is true, blowing the whistle on corruption, is beneficial in societal terms. However in these types of cases, the victims of pharmaceutical crimes do not get a cent from these fines. The government gets its cut, as do the lawyers, and the whistle blowers get theirs- of course. Victims of the crimes get nothing. Some whistle blowers only need to repeat what the first whistle blower said in an FCA complaint and they can get a claim to millions. Some just have to literally sit back, and wait for the cash to come. Personally,  I think this type of whistle blowing is based on greed more than anything else.

Even after a whistle is blown on a drug company’s corrupt practices, it’s often too late for those who have already been harmed. Furthermore, by the time the whistle blower’s claim comes to fruition (some can take a decade), the drug companies usually have continued their corrupt practices up until the case is unsealed. It’s only after they are fined, and they strike a deal with the DOJ, that the company, agrees to stop its unethical practices, and the profits are already made. Therefore, we could ask, who does whistle blowing benefit ultimately? and does the monetary incentive to a potential whistle blower    to expose dangerous and fraudulent practices, make any difference to patient safety in the longer term?

Personally, I don’t believe it does.

As I said, the damage is often already done.

We are not any safer despite these many fines for the pharmaceutical industry. The industry factors in the inevitable fines into their business plans. GSK, for example, paid their DOJ fine with cash already hoarded. The DOJ case made no impact upon their business, and it’s arguable whether it has impacted upon their corporate behaviour either. These settlements give us an illusion of justice which suits the governments and the pharmaceutical companies. It is not a deterrent, it could be doing quite the opposite in fact, because, the companies know the score now, they know what they can get away with. They’ve been given a paradigm to work with. These companies operate above the law, and their high ranking executives do not get punished.

Why are people like Piacentile not drawing attention to this scam and sham pseudo-justice?

GSK were fined 3 Billion dollars in 2012 by the US Department of Justice, for what was effectively, a literal global sociopathic scam fest; involving, mainly, the off label prescribing of many GSK products, spanning over a decade. In the case of one of the GSK drugs, Paxil (Seroxat), GSK promoted this drug to under-18’s despite information from its own trials into the drug revealing that it could be immensely harmful. GSK’s 3 Billion fine has done nothing to raise awareness of the dangers of Paxil.

In fact, the Paxil aspect was played down considerably in The department of Justice complaint (why?). The media, and the DOJ spun this 3 billion slap on the wrist, as if it was actual justice. It wasn’t. It was far from it. This was a token to GSK, it was a gift from Eric Holder. No justice was served. Patients died, and many continue to die from drugs like Paxil, it’s still being prescribed (and Avandia is too). The 3 billion fine, was a sick joke for patients prescribed these dodgy GSK drugs. The Paxil part of the DOJ complaint was an absolute joke.. in fact it was an insult to all those who were harmed.

As far as I am aware, Dr Joe Piacentile was also involved in some capacity in bringing later claims (jumping on board) the original DOJ complaint against GSK. It always seemed odd to me that, whistle blowers, Thomas Gerahty and Matthew Burke, came into the DOJ complaint years after it was first filed by Greg Thorpe. We don’t hear anything about these two individuals, or what they brought to the table, in regards to exposing GSK’s corrupt practices at the time that they joined the complaint years later. I suppose this kind of thing frustrates me, because people like Dr Joe, and these two whistle blowers- Burke and Gerahty, they could be driving real change, saving lives, speaking out on national TV about the truth of these bogus suits, but they choose, to just take the money and go silent. Meanwhile, bloggers like me, we’re left to do all the work, bringing awareness, with no resources. Anyhow, I’m not complaining, I’m satisfied with the work I’ve done, I did it for myself, and to warn others, so that they could be spared Seroxat/Paxil hell- and I achieved what I set out to do.

If anyone has made a difference in regards to bringing awareness to the Paxil/Seroxat scandal it is firstly the BBC Panorama team (in particular Shelley Jofre), and subsequently, bloggers such as Bob Fiddaman, Seroxat Secrets, and my own blog. Between us bloggers alone, we have thousands of blog posts and clocked immeasurable hours of campaigning for social justice, and patients rights, for over a decade. We have consistently blown the whistle on many topics, over many years, and we have tirelessly campaigned for victims of these drugs- not for monetary gain, but because we believe- as survivors of Paxil/Seroxat- we have a duty to warn others of the dangers of these drugs.

I don’t see much social justice campaigning about companies like GSK, or dangerous drugs like Seroxat/Paxil from any of these so called ‘professional whistleblowers’.

Why do they not speak out?

If Dr Joe is reading this, and I have got anything wrong (or perhaps I am off base with my perspective) please feel free to mail me on truthman30@gmail.com

Perhaps you can enlighten me to all the activism or causes you have supported -for patients rights to safe drugs- that you have done over the years?  or perhaps you have set up withdrawal clinics in the US for Paxil addicts to come off the poison in a safe, supportive environment? Or maybe you have campaigned behind the scenes for real justice for the survivors of  pharmaceutical crimes? There could be a lot I’m missing here, If so, I will gladly amend this post..

I won’t hold my breath though…

I have received threats through my mail before from certain people (and I don’t respond to threats, in fact- i ignore them- so   people really are wasting their time when they try that) but it’s rare to receive encouragement or support, this leads me to believe that for most whistle blowers, the monetary gain is the prime motivation the rest is mere cynical tokenism.

It seems to me that unless you were the first the blow the whistle, in a cases such as these, then you’re probably  just riding the gravy train…

It takes balls to be the first to blow the whistle..  because the first one is the first to take the risk… it takes courage to be the first.. the ones who follow are merely jumping on board.

They obviously see the dollar signs..

Thankfully, I have received occasional support from genuine people over these years of blogging and creating awareness- support from people who matter: mostly victims of GSK’s drugs, people who can’t get off Seroxat, or those who have lost loved ones to the drug, and some other good people who have sincere intentions.

And it’s these folks, who ultimately, I blog for..

There is an old saying that says, “how much would you be worth if they took away all your money?”

I might not have much in the bank but my soul is invaluable to me..

If my soul is my bank account, then it’s really very full indeed..


Disturbing, Revealing, And Absurd, Interview With Andrew Witty, The CEO Of GlaxoSmithKline..


Page_1


Andrew Witty

“Things go wrong. We have inevitably – of course, we go through all the processes with the regulators to get a drug to be as safe and effective as it can possibly be. But the reality is, every time a human takes a drug, it’s like a clinical trial. You don’t really know what’s going to happen.

Everybody can react a different way. So on the one hand, what is the story of the drug industry? The story of the drug industry is wonder drugs. On the other hand, it’s danger drugs. Those are the two extremes that we have.

It’s kind of unavoidable.”

(Translation: “often we release dangerous drugs like Seroxat and Avandia. We make billions on them and the people that get killed are just collateral damage, some of our drugs and products help people so we make up for the other GSK drug-induced deaths from poisons like Seroxat- that way. It all balances out in the end- we kill some, we help some.. it’s the nature of the pharmaceutical  business and kinda just tough if you get harmed”).

Evan Davis:

-“But you’re saying there are bad apples, and it goes wrong. Is that right, or is it – for example, in the China case. Was it that there was a bad apple and it went wrong, or was it that that was normal behaviour in certain markets, and it just got called out in that particular case?”

Andrew Witty:

-“For obvious reasons, I’m not going to get into all the details of that.”

(translation: “I don’t answer questions about our criminal behavior”)


Andrew Witty Sociopath


Mr Witty, “I think the bigger question” is: are you- and is your company-sociopathic?

It’s not often that we get to see the CEO of one of the biggest (and notably most corrupt) pharmaceutical companies on the planet (GSK) squirm like a little snake in an interview. Usually someone like Andrew Witty would have no fear of being asked awkward questions about fraud, bribery or corruption in interviews. Usually, Sir Witty would expect nothing short of the red carpet treatment from the media who court people like him. However, in the last seven minutes, of a recent interview between the BBC’s Evan Davis and Andrew Witty, the unethical behavior, of his company GSK, comes under intense scrutiny.

It’s important to note that under Andrew Witty’s tenure as CEO of GSK (since 2008), as recently as last year (2014) the company has been caught operating a massive bribery network in China, and the company is also under several investigations spanning several other countries for similar corruption allegations, and has been for some years now.  In 2012 GSK paid 3 billion to settle the biggest health care fraud in US history. There is also the issue of an ongoing serious Serious Fraud Office UK investigation and many other ethical issues concerning GSK’s unethical shenanigans which have yet to be resolved. These issues, serious though they are, don’t even touch upon the other GSK issues which affect people’s lives directly in horrible damaging ways- such as kids developing Narcolepsy from GSK’s Pandemrix, or kids dying from GSK’s notorious Seroxat (Paxil) drug.

GSK have been killing and harming consumers for decades.

Witty knows this, he just doesn’t care, because he is paid millions to care about GSK. His self interest, and the company’s self interest, values the profitability of GSK above human life, ethics and morality. That is the essence of his several minutes of uncomfortable avoidance in this fascinating interview.  Our lives mean nothing to him, he more or less said that in this interview. He said it’s “kind of unavoidable’.  What’s unavoidable? That people get killed and damaged? What is he saying- “tough shit- your life means nothing?” What’s unavoidable Andrew? That you corrupt psychiatrists, doctors? That your company lies about side effects of its drugs which leads to deaths?

He sees us (the public) as collateral damage. That much is clear.

As one of the direct casualties of GSK’s defective and dangerous drugs (Seroxat), I have to admit, I find it satisfying to see the CEO responsible for Seroxat, asked uncomfortable questions about GSK’s criminal behavior. His responses though, could be perceived as a master-class in how to avoid and deflect uncomfortable questions, however, despite his obvious skills in avoidance I think Witty comes across very badly in this video clip for a number of reasons.

His body language speaks volumes, when asked the first uncomfortable question at the beginning of this video, and when it’s obvious that the tone of the interview is about to change dramatically, Witty suddenly looks visibly annoyed, tense, fidgety, and uncomfortable. His squirming demeanor, followed by a big gulp, bowed head, contortions in his seat, and shameful expression, speak to me of a man who knows exactly how badly his company has behaved. I’d say he knows it all too well.

Nevertheless, this doesn’t stop him doing what he is paid (millions of pounds) to do: defend the company at all costs.

This is his own personal, ethical and moral weakness (he just doesn’t realize it).

(You’re defending the indefensible Witty- you sold your soul to GSK in 1985).

I don’t think that Witty was successful at all in this interview.

He doesn’t seem to realize that ‘normal’ (non sociopathic) people find it disturbing when they hear people trying to attempt the defend the indefensible.

I think he would have been better off being humble and apologizing for GSK’s widespread and well known criminality over the decades. Trying to pretend it didn’t really happen and is all just some kind of misconception is just an insult to people, we all know it did, there are hundreds documents and articles online, and on this blog, which detail GSKs vast and extensive criminality. People aren’t stupid, and the internet has documented all of GSK’s behavior now, no amount of deflection can argue with the facts…

The second video is taken from a recent interview from an Australian news piece with Jon Jureidini, a child psychiatrist from the university of Adelaide, who was also part of a RIAT team who re-assessed a GSK study (study 329) which came to the conclusion that GSK’s Seroxat (Aropax/Paxil) drug has harmed (and killed) many thousands of teens since it was first pushed on kids in the late 90’s.

GSK’s corporate spokesperson, Bernadette Murdoch, seems to have no problem coming out in defense of the indefensible. Similar to Witty, she tries to muddy the water with red-herring statements that are both meaningless, and also an insult, to all those who died, or were harmed, by GSK’s Seroxat (Paxil/Aropax) drug over the past few decades.

I’ve said it before, and I’ll say it again…

How do these corporate executives sleep at night?

Are they just sociopaths?

Do they not possess consciences?

(Kudos To Bob Fiddaman Of Seroxat Sufferers Blog for finding this video – see his post on it here)


For Recent news on GSK’s Dangerous Seroxat drug see here-

http://www.theguardian.com/science/2015/sep/16/seroxat-study-harmful-effects-young-people

“This is a very high rate of kids going on to become suicidal. It doesn’t take expertise to find this. It takes extraordinary expertise to avoid finding it.”

In an article published with the re-analysis, Peter Doshi, associate editor of the BMJ, said the new paper “has reignited calls for retraction of the original study, putting additional pressure on academic and professional institutions to publicly address the many allegations of wrongdoing.”

He said few trials had been as controversial as study 329, whose lead author was Martin Keller from Brown University. In 2002, the year after its publication, the US Food and Drug Administration said it should be considered a failed trial because the depressed adolescents taking the drug did no better than those on placebo.

In that same year, more than two million prescriptions for paroxetine were written for adolescents and children in the United States, on the back of an advertising campaign which claimed the trial had shown “remarkable efficacy and safety”.

GSK was fined $3bn in 2012 for fraudulently promoting the drug.


For further reading on GSK’s China bribery scandal see here-

http://www.bbc.com/news/business-29274822

China has fined UK pharmaceuticals firm GlaxoSmithKline $490m (£297m) after a court found it guilty of bribery.

The record penalty follows allegations the drug giant paid out bribes to doctors and hospitals in order to have their products promoted.

The court gave GSK’s former head of Chinese operations, Mark Reilly, a suspended three-year prison sentence and he is set to be deported.

Other GSK executives have also been given suspended jail sentences.


Bob Fiddaman Exposes All The Dodgy Doctors Greedily Gobbling From The Big Pharma Trough


http://fiddaman.blogspot.ie/2015/07/warning-pharma-payments-may-give-you.html?spref=tw

Thursday, July 02, 2015

WARNING: Pharma Payments May Give You Worms!

http://www.facebook.com/plugins/like.php?href=http://fiddaman.blogspot.ie/2015/07/warning-pharma-payments-may-give-you.html&layout=button_count&show_faces=false&width=100&%20action=like&font=arial&colorscheme=light

I now have access to the database that shows exactly how many Doctors GSK paid in 2014. I’ll be writing extensively about this over the coming weeks.

In the meantime, here’s a doctor who, it appears, either has some sort of binge eating disorder or has a bad case of worms.

DR. ROGER ABRAHAMS




His specialty is Allopathic & Osteopathic Physicians/Internal Medicine, Pulmonary Disease and he is based, according to the data, at 1265 Pineview Dr, Morgantown, WV 26505-2713

Here’s what GSK gave him for his food and beverages.

**Note how particularly peckish Dr Abrahams was on May 3**

GlaxoSmithKline Payments

FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
FOOD & BEVERAGE
1/27/2014
1/27/2014
2/25/2014
4/14/2014
4/21/2014
4/30/2014
5/2/2014
5/3/2014
5/3/2014
5/3/2014
5/3/2014
5/3/2014
5/4/2014
5/4/2014
5/4/2014
5/13/2014
6/6/2014
6/17/2014
6/17/2014
6/20/2014
7/28/2014
7/28/2014
8/11/2014
8/11/2014
8/18/2014
9/11/2014
12/2/2014
12/2/2014
12/11/2014
12/11/2014
$11.57
$1.20
$15.86
$13.05
$7.20
$23.85
$114.94
$17.73
$82.22
$60.81
$126.96
$15.71
$55.72
$49.37
$20.21
$93.40
$2.12
$1.03
$11.82
$47.85
$2.02
$9.58
$0.97
$8.56
$32.25
$13.85
$11.95
$2.85
$9.15
$0.43

And these were just payments from GSK.

Here’s what AstraZeneca paid him. He, it appears, really pushed the boat out on May 5, spending a total of $372 on food and beverages. That’s a fortnight’s groceries to the likes of your average person.

AstraZeneca Payments

Food and Beverage

Food and Beverage
Food and Beverage

Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
02/06/14
3/5/2014
3/5/2014
5/5/2014
5/5/2014
5/5/2014
5/5/2014
6/25/2014
12/18/2014
$14.99
$1.71
$14.16
$55.98
$135.00
$117.17
$63.91
$11.45
$14.67

Next we have Boehringer Ingelheim…


Boehringer Ingelheim Payments

Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
1/16/2014
5/21/2014
9/16/2014
10/8/2014
10/12/2014
12/10/2014
12/10/2014
$3.72
$11.46
$12.01
$12.01
$9.03
$40.64
$9.01

The there was Forest Pharmaceuticals…


Forest Pharmaceuticals Payments

Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
1/22/2014
2/10/2014
2/28/2014
3/26/2014
4/1/2014
4/7/2014
4/21/2014
5/8/2014
5/19/2014
6/9/2014
6/24/2014
7/14/2014
7/30/2014
9/5/2014
$11.72
$1.50
$9.30
$19.63
$15.97
$15.67
$1.78
$2.64
$5.60
$2.29
$1.92
$8.89
$7.28
$5.01

Just a couple of dining expenses from Genentech USA, Inc.

Food and Beverage7/30/2014$7.28 and 9/5/2014  – $5.01

Next up, Meda Pharmaceuticals, Inc.


Meda Pharmaceuticals, Inc Payments

Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
1/8/2014
5/14/2014
9/24/2014
10/20/2014
12/18/2014
$13.56
$12.90
$10.65
$11.65
$101.35

One from Merck Sharp & Dohme Corporation

Food and Beverage 11/19/2014$15.99

Mylan Specialty L.P. are next…

Food and Beverage 7/1/2014$17.58 and 7/1/2014 $1.76

Other minor one offs with other pharmaceutical companies, then Teva Pharmaceuticals USA, Inc

Teva Pharmaceuticals USA, Inc Payments

Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
Food and Beverage
3/20/2014
4/8/2014
5/13/2014
8/27/2014
10/9/2014
$10.35
$12.34
$15.51
$11.23
$13.54

Quite an appetite, I’m sure you’ll agree.

Payments to Roger Abrahams didn’t end there. He was also paid travel expenses and, as we shall see, for other miscellaneous activities.

TRAVEL & LODGING PAYMENTS

Before the integrity agreement was signed by GlaxoSmithKline in the recent $3 billion whisleblower lawsuit, Glaxo reps would often make payments for travel expenses. Blair Hamrick, who, along with others, blew the whistle on GSK, told me, “Back in the day, doctors were given the choice on one first class airfare, or could trade in for two coach tickets on these trips. They would always opt for two tickets and bring someone. After we filed they stopped doing that. “ Blair also informed me that, “There was speculation that a lot of doctors would paddle their expenses, in as much as they would turn in receipts without actually buying anything, to get extra money.”

On the subject of food and beverages Blair told me, “Back when we filed the case, Doctors would always bring spouses or guests. It was like a fully paid vacation. Right after the case was filed, they changed the rules to say that it was Doctors only. I don’t know whether they are sticking to the rule or not these days.”

This, in no way implies that Dr. Roger Abrahams was doing this. I just thought I’d give the reader some background into what Glaxo reps did and what the doctors, back then, chose to do.

Here’s Dr Abraham’s travel and lodging expenses.

AstraZeneca Pharmaceuticals LP

Travel and Lodging
Travel and Lodging
Travel and Lodging
Travel and Lodging
05/04/14
5/4/2014
5/5/2014
5/5/2014
$408.30
$1,115.22
$51.91
$78.71

Boehringer Ingelheim Pharmaceuticals, Inc.
Travel and Lodging
12/10/14
$1,116.70

GlaxoSmithKline

Travel and Lodging

Travel and Lodging

Travel and Lodging
Travel and Lodging
Travel and Lodging
Travel and Lodging
3/28/2014
5/2/2014
5/2/2014
5/4/2014
5/7/2014
8/20/2014
$529.50
$335.26
$44.00
$16.43
$25.76
$44.24

CONSULTING FEES PAID BY

Boehringer Ingelheim Pharmaceuticals, Inc.

1/28/2014 $150.00
3/2/2014      $682.50
3/26/2014 $1,000.00
3/26/2014 $4,000.00

GlaxoSmithKline

8/18/2014 $300.00

As always, I’ve saved the best until last.

The following falls under the vague category of…

“Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program.”

Boehringer Ingelheim Pharmaceuticals, Inc. AND **Boehringer Ingelheim Pharma GmbH & Co.KG

Compensation
Compensation
Compensation
Compensation
Compensation
Compensation
Compensation
Compensation**
Compensation**
Compensation**
Compensation**
Compensation**
12/15/2014
12/15/2014
12/15/2014
12/15/2014
12/15/2014
12/15/2014
12/15/2014
7/7/2014
7/10/2014
9/8/2014
10/20/2014
10/30/2014
$490.00
$4,321.00
$1,212.00
$1,461.00
$490.00
$1,461.00
$490.00
$188.31
$175.00
$521.86
$1,469.93
$562.00

GlaxoSmithKline

Compensation
Compensation
Compensation
Compensation
Compensation
Compensation
05/05/14
6/4/2014
6/11/2014
6/17/2014
6/19/2014
9/15/2014
$1,300.00
$800.00
$800.00
$800.00
$1,300.00
$1,450.00

Over the coming weeks I’ll be dissecting the database even more.

I’m now off for a sandwich… paid for by myself.

Bob Fiddaman.

Brazil Suspends Sale Of Seroxat (Paxil)


From Seroxat Sufferers Blog:

http://fiddaman.blogspot.ie/2014/05/brazil-suspends-sale-of-gsks-paxil.html

Thursday, May 08, 2014

Brazil Suspends Sale of GSK’s Paxil (Seroxat)

The National Health Surveillance Agency (ANVISA) have temporarily suspended the sale of GlaxoSmithKline’s antidepressant Paxil.

ANVISA are the Brazilian drug regulatory agency who regulate the drugs Brazilian citizens are prescribed.

GlaxoSmithKline sent ANVISA correspondence stating that batches of Paxil may have been manufactured with the use of active ingredient in the presence of residues.

It’s unknown where the contaminated batches originated from. The batches recalled are:

SH0040V (manufacture date, June 2013, and expiration date, June 2015),
RK0084V (manufacture date, August 2012, and expiration date, August 2014),
RJ0220V (manufacture date, July 2012, and expiration date, July 2014),
RJ0219V (manufacture date of July 2012, and expiration date, July 2014),
RC0113V (manufacture date, March 2012, and expiration date, March 2014)
RC0113V1 (manufacture date, March 2012, and expiration date March 2014).

Last month GSK Ireland were sent a warning letter from the FDA listing a series of violations regarding the state of their plant in Currabinny, Carrigaline, Cork. Paxil had become contaminated with material from Glaxo’s waste tank, which contained APIs [Active Pharmaceutical Ingredients], intermediates, and solvents.

Back in 2010 Glaxo plead guilty for failing to meet government standards for their drugs that were being manufactured at their Cidra plant in Puerto Rico.

Bob Fiddaman

And They Call Us “Conspiracy Theorists”…


From CNN MONEY 2005.

http://money.cnn.com/2005/10/31/news/newsmakers/fortune_rumsfeld/

Rumsfeld’s growing stake in Tamiflu
Defense Secretary, ex-chairman of flu treatment rights holder, sees portfolio value growing.
October 31, 2005: 10:55 AM EST
By Nelson D. Schwartz, Fortune senior writer

NEW YORK (Fortune) – The prospect of a bird flu outbreak may be panicking people around the globe, but it’s proving to be very good news for Defense Secretary Donald Rumsfeld and other politically connected investors in Gilead Sciences, the California biotech company that owns the rights to Tamiflu, the influenza remedy that’s now the most-sought after drug in the world.

Rumsfeld served as Gilead (Research)’s chairman from 1997 until he joined the Bush administration in 2001, and he still holds a Gilead stake valued at between $5 million and $25 million, according to federal financial disclosures filed by Rumsfeld.

The forms don’t reveal the exact number of shares Rumsfeld owns, but in the past six months fears of a pandemic and the ensuing scramble for Tamiflu have sent Gilead’s stock from $35 to $47. That’s made the Pentagon chief, already one of the wealthiest members of the Bush cabinet, at least $1 million richer.

Rumsfeld isn’t the only political heavyweight benefiting from demand for Tamiflu, which is manufactured and marketed by Swiss pharma giant Roche. (Gilead receives a royalty from Roche equaling about 10% of sales.) Former Secretary of State George Shultz, who is on Gilead’s board, has sold more than $7 million worth of Gilead since the beginning of 2005.

Another board member is the wife of former California Gov. Pete Wilson.

“I don’t know of any biotech company that’s so politically well-connected,” says analyst Andrew McDonald of Think Equity Partners in San Francisco.

What’s more, the federal government is emerging as one of the world’s biggest customers for Tamiflu. In July, the Pentagon ordered $58 million worth of the treatment for U.S. troops around the world, and Congress is considering a multi-billion dollar purchase. Roche expects 2005 sales for Tamiflu to be about $1 billion, compared with $258 million in 2004.

Rumsfeld recused himself from any decisions involving Gilead when he left Gilead and became Secretary of Defense in early 2001. And late last month, notes a senior Pentagon official, Rumsfeld went even further and had the Pentagon’s general counsel issue additional instructions outlining what he could and could not be involved in if there were an avian flu pandemic and the Pentagon had to respond.

As the flu issue heated up early this year, according to the Pentagon official, Rumsfeld considered unloading his entire Gilead stake and sought the advice of the Department of Justice, the SEC and the federal Office of Government Ethics.

Those agencies didn’t offer an opinion so Rumsfeld consulted a private securities lawyer, who advised him that it was safer to hold on to the stock and be quite public about his recusal rather than sell and run the risk of being accused of trading on insider information, something Rumsfeld doesn’t believe he possesses. So he’s keeping his shares for the time being.

http://www.smh.com.au/comment/tamiflu-is-the-new-snake-oil-20140416-zqvj8.html

Tamiflu is the new snake oil

Date
April 16, 2014

Dr Joe Kosterich

Millions has been wasted on Tamiflu.Millions has been wasted on Tamiflu. Photo: fairfax

In days of old when the snake oil salesman came to town folks would gather round to hear of miracle cures. Those who were sufficiently impressed would buy some of the salesman’s wares to cure colds, sore toes or a myriad of other ailments. The snake oil salesman would then get back onto his cart and go to the next town.

Times change. Today we have scientific channels, advisory panels and rigorous process to make sure that whatever claims are made are verifiable.

So surely governments around the world could not spend billions of dollars stockpiling a drug which does not actually do anything?

Tamiflu has been a big waste of money.Tamiflu has been a big waste of money.

Could doctors, advisory panels, and health departments have been sold modern day snake oil?

Unfortunately, the answer is yes!

The anti viral drugs Tamiflu (oseltamvir) and Relenza (zanamivir) have been promoted as a treatment for influenza. But most specifically, they have been claimed to reduce transmission of influenza and reduce complications such as pneumonia. Governments have bought them so that they can be released in the event of an epidemic.

But recent research has found that these drugs are little more than today’s snake oil potions. A review of 46 studies on more than 24,000 people has shown that they do not prevent people catching the flu. They do not reduce the rate of complications or hospitalisations. At best, they might reduce the length of the illness by about half a day.

Let me repeat that- it shortens the course of influenza by half a day, at best!

How could so much money get spent on something of so little value? That is because the drug manufacturers refused to release most of the data that is now available.  Only information from drug trials, which showed a positive effect from the drug, was previously published.

The British Medical Journal and independent Cochrane Collaboration had been fighting for four years to get hold of all the data so that it could be independently examined and to answer the very basic question – does it work?

Obviously the manufacturers are keen to put the best spin on their products. But they are not the only ones culpable here. There are numerous problems to fix.

Between 48% and 89% of researchers involved in clinical trials of new treatments have been found to have undeclared conflicts of interest. This occurs  where the company that has a new drug being studied may pay them directly or indirectly.

Medical research needs to be cleaned up.

Governments look to advisory panels for independent advice. Some 75% of doctors on panels, which make recommendations about disease definitions and management, have ties to the pharmaceutical industry.

Any advisory board must have totally independent members.

 The facts show that every influenza “epidemic” since 1918 has had fewer deaths than the one before.  Predictions about millions of deaths from, Avian flu, SARS and Swine flu all turned out to be completely wrong.

Each year in Australia there are around 2500 deaths associated with influenza. Some 98% of these are due to secondary pneumonia in people of an average age of 87(which is older that the average life expectancy).

The annual “killer flu” hype needs to be toned down.

Is the flu really so fearsome? For the vast majority of people it will be up to a week of feeling unwell followed by a full recovery. There are exceptions and whilst tragic, they are very rare and are not always understood or preventable.

Governments like to be seen to be doing something. Wendy Barclay from Imperial College London best summed this up telling Reuters: “If another pandemic came tomorrow, and the government had no drug to treat thousands of influenza infected patients, I imagine there would be public outcry”.

She sums the situation up very well – the public expects the government to provide a medication, which does not work for an illness, which will go away by itself.

Maybe deep down we still want to buy the snake oil and the salesman is still ready to assist us.

Read more: http://www.smh.com.au/comment/tamiflu-is-the-new-snake-oil-20140416-zqvj8.html#ixzz2z76m6aXj

Irish Times: “GSK needs to get drugs working in Cork”


http://www.irishtimes.com/business/sectors/health-pharma/gsk-needs-to-get-drugs-working-in-cork-1.1753617

GSK needs to get drugs working in Cork

 

Recent US warning an embarrassment

It seems strange that GSK allowed events to culminate in a warning letter: its sense of urgency now in dealing with the problems is welcome.It seems strange that GSK allowed events to culminate in a warning letter: its sense of urgency now in dealing with the problems is welcome.

Tue, Apr 8, 2014, 01:01

Tomorrow is the deadline for GlaxosmithKline to inform the US Food and Drug Administration how it intends to ensure compliance with quality standards at its Currabinny plant in Cork.

The recent warning letter issued by the US regulator is a significant embarrassment for the pharma giant, which places great store by its attention to detail in its supply chain.

In this case, an inspection by the US authorities found paroxetine, the active ingredient in popular antidepressants Paxil and Seroxat, could have been contaminated. The issue originally arose more than a year before the inspection last October, but GSK’s remedial actions were still deemed insufficient as recently as March, resulting in the warning letter.

It is the latest in a series of mishaps by the British drug maker, which is also struggling to repair its reputation in China as an investigation continues there into allegations of bribery. The inquiry has been unsettling for Andrew Witty and his management team, for whom emerging markets have always been a key target for growth and for which integrity and ethics are regularly cited as cornerstones on which the company operates.

The company found itself at the centre of yet more unwelcome publicity – this time over allegations of bribery in Iraq. The latest controversy centres on claims the company hired government-employed doctors and pharmacists in Iraq as paid sales representatives to improperly boost use of its products.

The Currabinny warning letter is the first for the company’s business in Ireland. Failure to deal decisively with the issues raised could see its output locked out of the pivotal US market and approval withheld for new drugs to be produced from Cork. That would swiftly signal the end of the plant.

It seems strange that GSK allowed events to culminate in a warning letter: its sense of urgency now in dealing with the problems is welcome.

Bob Fiddaman E-mails Ian Hudson (Former GSK Exec and Current CEO of MHRA)


http://fiddaman.blogspot.ie/2013/11/email-to-ceo-of-mhra-ian-hudson.html

Saturday, November 09, 2013

Email to CEO of the MHRA, Ian Hudson

I’ve just flicked the following email to the new MHRA Chief, Ian Hudson.

Any reply will also be made public.

Dear Mr Hudson,

As I understand you are now Chief Executive of the MHRA. I’d congratulate you but we both know that I’d be lying with those congratulations given your past links to GlaxoSmithKline and Seroxat.

That aside, I have to remain professional.

My question to you is one of great concern and one that I shall be making public on my blog http://fiddaman.blogspot.com

Are you, or do the MHRA plan to reevaluate the current recommendations that pediatrics should not be prescribed SSRi’s?

I ask as it has come to light that MHRA consultant, Stephen J W Evans, has recently co-authored a study where he and the other authors call for a re-evaluation of the current prescription of SSRIs in young people – Back story here.

This email, along with your answer, if you are brave enough to answer that is, will be published on my blog.

Best wishes

Bob Fiddaman.

Glaxo’s Chinese Nightmares Continue…


http://www.bloomberg.com/news/2013-08-07/race-to-publish-shows-glaxo-zeal-to-get-leg-up-in-china.html

Liu Xuebin recalls working 12-hour shifts and most weekends for months, under pressure to announce research results that would distinguish his GlaxoSmithKline Plc (GSK) lab in Chinaas a force in multiple sclerosis research.

It paid off — for a while. Nature Medicine published findings about a potential new MS treatment approach in January 2010 and months later Liu was promoted to associate director of Glaxo’s global center for neuro-inflammation research in Shanghai. Two months ago, his career unraveled. An internal review found data in the paper was misrepresented. Liu, 45, who stands by the study, was suspended from duty on June 8 and quit two days later.

His story, told in a cafe a short stroll from his former workplace, offers insight into Glaxo’s zeal to succeed in the world’s fastest growing major drugs market, where the London-based company languishes in 12th place. Glaxo is now the subject of a corruption probe, and three other drugmakers have been, or are in the process of being, examined by authorities in China, where intense competition built incentives for employees to bend rules and cut corners.

“It was extremely tough, we were all very tired and everyone was competing to be first,” Liu said in an interview last week. “Everyone had many projects. The more you do, the more likely you will make mistakes.”

The China-born scientist was the first of 18 authors on the 2010 paper, which included graphs later shown to have incorrectly labeled healthy human cells as being those frommultiple sclerosis patients. Liu says he opposes a retraction of the paper.

R&D Head Fired

“It was an honest mistake, and it doesn’t affect the findings,” he said, sipping a cappuccino. “I can confidently say that I can recreate the result in any laboratory.”

Glaxo, the U.K.’s largest drugmaker, disclosed the error in astatement on its website on June 10, the day Liu resigned. The head of Chinese research and development was fired and three others were placed on administrative leave pending a final review, it said. The paper, titled “Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease” was from preclinical, early stage research and didn’t directly involve patients.

‘Clear Evidence’

“Our thorough investigation found clear evidence of data misrepresentation and 16 of the 18 authors on the paper have agreed it should be retracted,” David Daley, a Glaxo spokesman inLondon, said in an e-mailed response to questions. “We will not tolerate activity and behavior that falls short of the high standards expected from our employees.”

Daley didn’t respond to a question regarding the competitive environment Liu described. Nature Publishing Group declined to comment specifically on the status of Liu’s paper.

“The only people who can retract papers are authors or editors,” Editor-in-Chief Phil Campbell said in an Aug. 3 e-mail. “Editors may be requested to retract a paper over the heads of authors, whether by the authors’ institution or company or by anyone else.”

In those situations, Nature’s editors will decide in consultation with the authors, Campbell said.

The disputed research isn’t part of the investigation of Glaxo China announced in late June by the nation’s Public Security Ministry of alleged economic crimes involving 3 billion yuan ($489 million) of spurious travel and meeting expenses, and trade in sexual favors. Glaxo’s head ofemerging markets Abbas Hussain said on July 22 after meeting with government officials in Beijing that some of its employees may have broken China’s laws. The drugmaker has said it’s cooperating with the government’s investigation.

Rapid Expansion

Still, Liu’s experience tells of the rapid expansion in research from immune diseases to herbal medicines that Glaxo underwent in China and of the competitive environment in which he and colleagues worked.

Johnson & Johnson was fined for monopolistic practices last week. Eli Lilly & Co. was reviewed earlier this year by authorities in Shenyang, the company said on Aug. 1. An unidentified whistle-blower alleged that Sanofi gave about 1.69 million yuan ($276,000) in bribes to 503 doctors in China, the 21st Century Business Herald reported today.

Sanofi “takes very seriously” the allegations in the report and has established processes in place for reviewing and addressing such issues, the company said in an e-mailed statement today, adding it was premature to comment further.

‘Virgin Territory’

“For Glaxo and for other multinationals, China represented virgin territory — it could build up its sales force and R&D effort in parallel there,” said Navid Malik, head of life sciences research atCenkos Securities Plc (CNKS) in London. “Because it’s still under-penetrated, they could think about how to target certain disease areas where they can build sales infrastructure and roll out their R&D cheaply and efficiently.”

The China-based research units of most global drugmakers tend to support centers located in the U.S. and Europe. Glaxo’s facility in Shanghai was different: it was conceived to lead the company’s global efforts in research into neurodegeneration.

It would “eventually direct the global discovery and development activities” for disorders such as multiple sclerosis, Parkinson’s disease and Alzheimer’s disease, Glaxo said in a May 2007statement.

Establishing the center didn’t only enable Glaxo to tap a pool of talented Chinese researchers — many of whom had worked overseas, as Liu had — it was also politically savvy, said Fabian Wenner, a health-care analyst with Kepler Capital Markets in Zurich.

‘Solid Presence’

“If you want a government contract, it’s easier for you to negotiate if you have a solid presence in China,” Wenner said in a telephone interview.

Liu, who moved to the U.S. after obtaining a doctorate in immunology from Beijing Medical University in 1999, was part of the diaspora of Chinese researchers returning home.

A U.S. permanent resident, he worked as a senior biologist at the Bethesda, Maryland-basedNational Institutes of Health before becoming the 30th person hired at Glaxo’s Shanghai research center in December 2007. The center, located in a technology park on the eastern outskirts of Shanghai, now has a staff of about 500.

“This was my first job in industry and there was a very different culture,” Liu said behind thick, rimless glasses and dressed in a short-sleeve checked shirt tucked neatly into his belted trousers. “I was also not experienced with compliance back then, and we didn’t pay enough attention to things such as recording of reports from our collaborators.”

Colleague Competitors

There was also a culture in which Glaxo scientists were grouped into competitive teams, known as discovery performance units, which vied internally for funds every three years, he said. Those who failed to meet certain targets risked being disbanded.

The publication of Liu’s paper in Nature Medicine was initially lauded by Glaxo, he said, adding that the company rewarded his 30-strong team with 20,000 yuan ($3,300), which they spent on a team-building trip.

“We heard Pfizer (PFE) and a few other universities and research institutes were working on something similar,” Liu said of his research. “If someone else had published ahead of us, it would have screwed up our plans. The novelty would have been lost.”

He’s now unemployed and contemplating returning to the U.S. to escape damage done to his reputation in China.

“This situation has destroyed my past and maybe even my future, but I still hope someday to be back researching drugs,” Liu said.

To contact Bloomberg News staff for this story: Daryl Loo in Beijing at dloo7@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net

%d bloggers like this: